Sep 28, 2006 by Brian LawlerMyriad Moves ForwardThe biotech's new cancer candidate passes phase 1 trials.
Sep 28, 2006 by Brian LawlerAmgen Secures Its FutureFDA approval for the company's colorectal cancer drug is good news for its future prospects.
Sep 27, 2006 by Brian LawlerEnormous Interest in AnorMEDGenzyme and Millenium vie to purchase the Canadian biotech.
Sep 27, 2006 by Brian LawlerOne Step Forward for InterMuneThe company's lead drug will enter phase 1 trials, bringing potential good fortune to investors.
Sep 26, 2006 by Brian LawlerFour-Bagger Biotech in One DayAcorda's shares zoomed up, but potential investors should be cautious.
Sep 26, 2006 by Brian LawlerGPC's Trial GleeA new platinum-based cancer treatment yields encouraging results.
Sep 26, 2006 by Brian LawlerA Savior for Cephalon?The FDA's approval of Fentora comes just in time for the drug company.
Sep 26, 2006 by Brian LawlerCVT's Looming Date With DestinyA pivotal trial for its lead drug, Ranexa, is nearing completion.
Sep 25, 2006 by Brian LawlerDemystifying the Social Security "Crisis"There are relatively simple solutions to a looming problem.
Sep 25, 2006 by Brian LawlerMerck's Positive ContributionBad press from Vioxx shouldn't overshadow the company's new offering.
Sep 22, 2006 by Brian LawlerHospira's New Mate Down UnderHospira announces an acquisition, but the move means adding on a lot more debt.
Sep 22, 2006 by Brian LawlerThe Truth About Dietary SupplementsUnwary customers could suffer from supplements' lack of government scrutiny.
Sep 22, 2006 by Brian LawlerHealthy Rec for OraSureThe CDC recommends that HIV testing become routine for everyone aged 13-64 -- good news for medical diagnistic companies.
Sep 21, 2006 by Brian LawlerImClone's Board ShakeupA new face in the boardroom heralds change for the troubled company.
Sep 21, 2006 by Brian LawlerAnother Partner for BiogenThe pharmaceutical enlists help to thwart a troublesome illness.
Sep 21, 2006 by Brian LawlerSayonara, SeronoThe tiny, struggling drugmaker succumbs to a surprise buyout.
Sep 19, 2006 by Brian LawlerA Long Wait for MannKindThe company's inhaled insulin might not reach the market for several years, if it does, but it's a big market.
Sep 19, 2006 by Brian LawlerBarr's Winning BidThe pharmaceutical wins its tug-of-war for generic drug firm Pliva.
Sep 19, 2006 by Brian LawlerImClone Down but Not OutLegal fees loom as ImClone loses a patent dispute.
